Clinical Trials Logo

Marijuana Abuse clinical trials

View clinical trials related to Marijuana Abuse.

Filter by:

NCT ID: NCT04595318 Completed - Tobacco Dependence Clinical Trials

Varenicline for Co-occurring Cannabis and Tobacco Use

Start date: January 2015
Phase: Phase 4
Study type: Interventional

Pilot, eight week, open-label, within-subject cross over trial of four weeks of standard clinical care (SCC) in an outpatient substance abuse treatment program and four weeks of SCC and varenicline among current and former tobacco smokers with frequent cannabis use.

NCT ID: NCT04587700 Completed - Cannabis Clinical Trials

Analgesic Consumption in Chronic Marijuana Users Following Orthopedic Trauma Surgery

Start date: September 21, 2020
Phase:
Study type: Observational

Marijuana use has increased since its legalization in Canada and many believe that it may help patients that are experiencing chronic pain. The investigators want to assess if patients who have used marijuana chronically will need more medication to control their pain after they have undergone orthopedic trauma surgery (ex. Hip, femur, humerus fractures etc.). In this study, the investigators will identify chronic marijuana users (ie. those using for 3 months or more) who are undergoing orthopedic trauma surgery to assess how much pain medication they need post-operatively and compare this with non-users. The investigators will also evaluate their pain scores, pain medication use and other complications that they may have during or after their surgeries, including any nausea/vomiting, heart or breathing problems.

NCT ID: NCT04567238 Completed - Cannabis Use Clinical Trials

Impact of Reduced Cannabis Use on Functional Outcomes (R33 Phase)

FOCUS
Start date: March 19, 2021
Phase: N/A
Study type: Interventional

Nearly 20 million Americans report use of cannabis in the past month, and heavy cannabis use has increased by nearly 60% in the U.S. since 2007. Heavy cannabis use is associated with lower educational attainment, reduced physical activity, increased rates of addiction and unemployment, and neuropsychological deficits. Studies suggest that cannabis use is also associated with increased mental health symptoms, drugged driving, and traffic accidents. While there is evidence that sustained abstinence can lead to improvements in the functional outcomes of former users, the degree to which reductions alone (i.e., not sustained abstinence) in cannabis use might be associated with positive changes in functional outcomes is unknown. This is a critical gap in the literature, as many interventions for cannabis and other drugs are associated with decreases in frequency and quantity of use, but fail to achieve an effect on overall abstinence rates. The objective of the present research is to use ecological momentary assessment (EMA), a real-time, naturalistic data collection method, to prospectively study the impact of reduced cannabis use on functional outcomes in heavy cannabis users. Contingency management (CM) will be used to promote reductions in frequency and quantity of cannabis use. CM is an intensive behavioral therapy that is highly effective at producing short-term reductions in illicit drug use. We have recently developed a novel approach that leverages mobile technology and recent developments in cannabis testing. We have pilot-tested this approach with heavy cannabis users and found that it is an acceptable and feasible method. The present research will use this technology in conjunction with EMA methods to study the impact of reduced cannabis use on key functional outcomes. Our central hypothesis is that reductions in frequency and quantity of cannabis use will lead to positive changes in cannabis users' mental health, self-efficacy, physical activity, working memory, health-related quality of life, and driving behavior. The rationale for this research is that it will provide the first and only real-time data concerning the potential impact of reductions in cannabis use on functional outcomes. As such, the findings from the present research will directly inform ongoing efforts to include reductions in illicit drug use as a valid, clinically-meaningful outcome measure in clinical trials of pharmacotherapies for the treatment of substance use disorders.

NCT ID: NCT04495725 Completed - Chronic Pain Clinical Trials

Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain

ReLeaf-V
Start date: October 6, 2020
Phase: N/A
Study type: Interventional

This study will examine how discounted vouchers for medical cannabis use affects opioid analgesic use in adults with chronic pain. Our study findings will have critically important implications to shape clinical care and medical cannabis policies.

NCT ID: NCT04461756 Completed - Healthy Volonteers Clinical Trials

Safety and Pharmacokinetics of Vaped Cannabis in Healthy Volunteers

Start date: November 1, 2018
Phase: Phase 1
Study type: Interventional

The primary objective of this study was to evaluate the pharmacokinetics (PK) of THC, 11-OH-THC and CBD following a single inhaled dose of PPP001 administered by vaporization. The secondary objective of this study was to determine the safety and tolerability of THC and CBD after a single inhaled dose of PPP001 administered by vaporization in healthy volunteers.

NCT ID: NCT04402554 Completed - Clinical trials for Rheumatoid Arthritis

Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis

CannabisRIC
Start date: May 19, 2020
Phase:
Study type: Observational

Patients with inflammatory rheumatism very often have residual pain that is not easily relieved by conventional treatments. They can then use non-drug methods, such as physiotherapy, hypnosis or even cannabis. The aim of this study is to assess the percentage of patients who use cannabis to better relieve their pain or anxiety in chronic inflammatory rheumatism.

NCT ID: NCT04360044 Completed - Migraine Clinical Trials

Efficacy of Inhaled Cannabis for Acute Migraine Treatment

Start date: November 20, 2020
Phase: Phase 2
Study type: Interventional

This crossover study will evaluate 3 different treatments of vaporized cannabis (THC, THC/CBD mix, and CBD) and vaporized placebo cannabis for the acute treatment of migraine.

NCT ID: NCT04320537 Completed - Clinical trials for Brain Metabolic Changes During Marijuana Abstinence

Brain Neurochemical Profile During Marijuana Abstinence

Start date: July 1, 2017
Phase:
Study type: Observational

We have interviewed more than 120+ candidates and recruited 44 chronic marijuana users and 11 non-user healthy controls: 26 of the 44 MJ users actually participated in the study, 6 of the 26 MJ participants dropped out after their baseline magnetic resonance (MR) visits and the remaining 20 participants completed the study protocol, namely completed three MR visits for measurement of brain metabolites (baseline, day 7, and day 21); among the 11 healthy controls, 10 completed the study protocol. We are currently analyzing collected data and preparing manuscripts for peer reviewed journals.

NCT ID: NCT04316741 Completed - Cannabis Use Clinical Trials

Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use

Start date: October 19, 2020
Phase: N/A
Study type: Interventional

The purpose of the study is to develop and test social media interventions to help young people increase well-being and reduce risky behaviors. The study will help researchers learn about ways to deliver wellness information in a way that is appealing and helpful to young people who use Snapchat.

NCT ID: NCT04314804 Completed - Healthy Volunteers Clinical Trials

Safety and Pharmacokinetics of Smoked Cannabis in Healthy Patients

Start date: March 1, 2017
Phase: Phase 1
Study type: Interventional

No actual human data for pharmacokinetics, metabolism, safety, pharmacodynamics, nor efficacy parameters are available for inhaled medical cannabis. This study was designed to investigate the innocuity and tolerability levels as well as the pharmacokinetic profile of this combination when smoked/inhaled as intended in clinical therapeutic use (i.e. patients with neuropathic pain). Consecutive dosing (over a period of 7 days) should allow to test the tolerability of chronic administration. In addition, the impact of the THC/cannabidiol pharmacological activity on the cognition activity, cognitive test will be performed before and throughout the treatment and compared to the plasma levels of THC/cannabidiol following single and multiple dosing.